

***bla* TEM, *bla* SHV and *bla* CTX-M-15 Extended spectrum beta-lactamase produced by *Acinetobacter baumannii*, *Enterobacter cloacae* and *Proteus mirabilis* from pregnant women in three secondary health care facilities in south-south, Nigeria.**

Abstract

Background\purpose

Based on fact there is high urinary tract infection and increasing treatment failure among pregnant women and this has led to increased mortality and morbidity among pregnant women, and increased stay in the hospital.

This study was conducted to evaluate the prevalence of antimicrobial resistance and distribution of *bla*TEM, *bla*CTX-M-15 and *bla*SHV genes among *A. baumannii* , *P. mirabilis* and *E. cloacae* strains isolated from urine samples from pregnant women attending antenatal at three secondary health care facilities south-south Nigeria.

Methods:

A. baumannii, *P. mirabilis* and *E. cloacae* strains were isolated and identified using Microbact 24E. The disc diffusion and combined discs methods were used for testing antimicrobial susceptibility .The presence of ESBL was detected using Double Disk Synergy Test (DDST) and CHROMagar respectively. Plasmid extraction was carried out following the protocol of ZR Plasmid Miniprep-Classic extraction kit. Finally, the frequency of resistant genes including *bla*TEM, *bla*CTX-M-15 and *bla*SHV in selected 50 ESBL producing isolates was studied by PCR and using designed primers.

Result

A total of 252 clinical isolates was collected from three secondary health care facilities in south-south, Nigeria. ESBLs were found in 231 (92%) isolates. *bla*CTX-M-15 was the commonest genotype (58.3%), followed by *bla*SHV (43.3%) and *bla*TEM (43.3%).

Conclusion

ESBL positive strains of *Enterobacter cloacae*, *Acinetobacter baumannii* and *Proteus mirabilis* are increasingly found in isolates from pregnant women. The widespread use of antibiotics has caused shifts in bacterial development to overcome the existing mechanisms of combating bacterial infections. These strains become resistant to frequently used antibiotics and they can

34 pass the gene to other bacterial strains, the quick detection of these strains in clinical laboratories
35 an essential step. The frequency of genes encoded ESBL isolates of *Enterobacter cloacae*,
36 *Acinetobacter baumannii* and *Proteus mirabilis* may be due to abuse and misuse of antibiotics.
37

38 **Key Word: ESBL blagene , PCR, UTI**

39

40 INTRODUCTION

41 Currently, the challenge of gradually increasing resistance to antibiotics has affected the entire
42 world. The hydrolysis and inactivation of beta-lactam antibiotics, through the production of
43 beta-lactamase has been one of the most main resistance mechanisms of many bacterial species,
44 especially in the family Enterobacteriace (Akcem *et al.*, 2004). Gram-negative pathogens is
45 increasingly associated with ESBLs, hence resulting in the resistance to beta-lactam antibiotics
46 (Kimura *et al.*, 2007).

47 ESBL positive enterobacterial species are widely disseminating throughout the world (Timko,
48 2004).The main reason for development of resistance is mainly the selection and preferential
49 growth of resistant bacteria, together with inhibition of susceptible strains from prolonged use of
50 antibiotic. Extended-spectrum -lactamases (ESBLs) were first described in the 1980s and they
51 have been detected in Gram-negative bacilli (Kiratin *et al.*, 2008; Cheng *et al.*, 2008; Morris *et*
52 *al.*, 2003).

53 A typical mechanism of AMR is the production of extended-spectrum beta-lactamase. (ESBL)
54 enzymes, which confer resistance to penicillins, cephalosporins, and monobactams, but not to
55 cephamycins and
56 carbapenems (Paterson and Bonomo, 2005; Pitout *et al.*, 2005).

57 Presently there is an increase in the emergence of ESBL producing bacteria. The increasing
58 resistant to beta-lactam antibiotics used in treating urinary tract infections (UTIs) has made the
59 treatment very challenging and frequently resistant to many of the antimicrobial agents
60 recommended for the treatment of such infections (Ben-Ami R, Rodriguez-Bano *et al.*, 2009).
61 Most ESBLs belong to the CTX-M, SHV (Sulphydryl variable) and TEM (Temoniera) families.
62 Due to the production of multiple enzymes such as the inhibitor-resistant ESBL variants and
63 plasmid-borne AmpC, ESBL phenotypes have become more complex (Mohanty *et al.*, 2010).
64 Commercial available chromogenic media such as CHROMagar(Paris, France) have been used
65 to detect ESBL production. Chromogenic culture media is a rapid culture based methods used for
66 detection of ESBL and presumptive organism identification. The media has a chromogenic
67 enzyme substrate as a detection system. Chromogenic substrates consist of chromophor which is
68 linked to an enzyme-recognizing part such as carbohydrate, amino acids or phosphate. Specific
69 enzymes produced by the target micro-organism will cleave to the chromogenic substrate
70 liberating the chromophor which highlight the micro organism by coloration of the grown colony
71 (Gazin *et al.*, 2012). The aim of this study was to isolate and identify the types of extended
72 spectrum beta-lactamases

73 genes (ESBL) produced by *A.baumannii* and *Enterobacter cloacae* and *Proteus mirabilis*.

74 **Materials and Method**

75 **Sample Collection**

76 The study was carried out within a period of six months. A total of 660 urine samples were
77 collected from pregnant women attending antenatal at the three secondary health care facilities
78 between July to December, 2018. All pregnant women who were not on any antibiotics and
79 willing to participate were included in the studies, while those on any antibiotic therapy were
80 excluded from the studies.

81 Mid stream clean- catch urine samples were collected and inoculated on MacConkey and
82 CHROMagar ESBLE and incubated at 37°C for 24 hours. They were examined for growth and
83 colony counts yielding bacterial growth of 10⁵/ml of urine were taken to be significant. Samples
84 were Gram stained and also subjected to Microbact 24E identification.

85 **Antimicrobial Susceptibility Testing**

86 Antibiotic susceptibility was determined by the disk diffusion method on Mueller-Hinton agar
87 (Oxoid, UK) according to Clinical and Laboratory Standard Institute (CLSI) guidelines. ESBLE-
88 producing isolates were screened using double-disk synergy test in accordance with CLSI
89 guidelines (CLSI, 2012). According to CLSI guidelines isolates showing inhibition zone size of
90 ≤ 22 mm with Ceftazidime (30µg), ≤ 25 mm with Cefotaxime (30 µg), ≤ 27 mm with Azetronam
91 (30 µg) and ≤ 22 mm with Cefodoxime (10 µg) was identified as potential ESBLE producers and
92 shortlisted for confirmation of ESBLE production (CLSI, 2010). *E. coli* ATCC 25922 and *S. aureus*
93 6571 were used as quality control strains.

94 **Double Disk Synergy Test**

95 Double disk synergy test as described by Jarlier *et al.*, [32] was used to confirm ESBLE
96 production. Test isolate was swabbed on the surface of Mueller Hinton agar, then placement of a
97 ceftazidime disk close (20 or 30 mm) to an amoxicillin-clavulanate disk on a plate inoculated
98 with the test organism. A clear extension the zone of inhibition around the disk towards the
99 amoxicillin-clavulanate disk that is centrally placed indicates the production of ESBLE. This
100 extension occurred due to the fact that the clavulanic acid present in the augmentin disc
101 inactivated the ESBLE produced by the organism.

102 Inoculation was also done on CHROMagar ESBLE, a completely new and innovative
103 chromogenic medium designed specifically for the Screening of Extended Spectrum β -
104 Lactamase-producing Enterobacteria (ESBLE) [33]. Incubation was done for 18-24hrs.
105 *Escherichia coli* produced pink to burgundy colouration of β -glucuronidase-producing colonies
106 *Klebsiella*, *Enterobacter*, *Serratia*, *Citrobacter* (KESC): green/blue to brownish-green colouration
107 of β -glucosidase-producing colonies. *Proteaeae* (*Proteus*, *Providencia*, *Morganella*)
108 produced dark to light brown colouration.

109

110

111 **Ethical consideration**

112

113 Ethics committee of Akwa Ibom State Ministry of health, provided ethical clearance for the
 114 study. Participants' privacy and confidentiality have been assured (no names have been used,
 115 only serial numbers were used) and all data and results have been handled and treated
 116 confidently. Ref:MH/PRS/99/VOL.IV/200

117 **Statistical Analysis**

118 The SPSS statistical package version (20.0) was used for statistical analysis. A p-value <0.05
 119 was considered as statistically significant.

120 **Plasmid DNA Analysis**

121 Plasmid extraction was carried out using ZR Plasmid Miniprep-Classic extraction kit according
 122 to the manufacturers instruction

123 **Table 1: Primer sequences used to amplify and β -lactamase genes by the PCR technique**

Gene	Target	Primer	Product size (bp)	Reference
<i>bla</i> _{TEM}	β -lactam	F: ATAAAATTCTTGAAGACGAAA	1080	Sharma <i>et al.</i> , 2010
		R: GACAGTTACCAATGCTTAATC		
<i>bla</i> _{SHV}	β -lactam	F:CACTCAAGGATGTATTGTG	928	Sharma <i>et al.</i> , 2010
		R: TTAGCGTTGCCAGTGCTCG		Sharma <i>et al.</i> , 2010
<i>bla</i> _{CTX-M-15}	β -lactam	F:CGCTTTGCGATGTGCAG R: ACCGCGATATCGTTGGT	550	

124 **Detection of ESBL Genes types by PCR**

125 ESBL producing isolates were amplified using *bla* TEM/SHVCTX-15, specific primers listed in
 126 Table 1. The reaction was performed in Gene Amp PCR system 9700 thermocycler (Thermo
 127 Electron Corporation, USA) under the following conditions: Initial denaturation at 94°C for 5
 128 minutes followed by 35 cycles of 30 seconds denaturation at 94°C, 30 seconds annealing at 58°C,
 129 60 seconds extension at 72°C and a final extension at 72°C for 7 minutes. Polymerase chain
 130 reaction (PCR) products was separated by electrophoresis in 1.5% agarose gels and stained with
 131 ethidium bromide .A molecular marker (DNA laddah size range: 10 kb) was used to assess PCR
 132 product size.

133

134 **RESULT AND DISCUSSION**

135 During a six-month period, a total of 252 uropathogens from pregnant women attending
 136 antenatal at Government general hospital, Eket, Ikot Ekpene and Oron were identified. 231

137 isolates were confirmed as potentially ESBL producers using DDST and CHROMagar ESBL.
138 Occurrence of ESBL isolates was as follows: *Enterobacter cloacae* (57%), *A. baumannii* (13.5%),
139 *Proteus mirabilis* (32%), (Table 2).

140 Fifty ESBL producing isolates were selected for plasmid DNA extraction and *bla* gene
141 amplification: *P. mirabilis* n=12, *A. baumannii* n=20, *Enterobacter cloacae* n=18. Plasmid DNA
142 of size 10kb was extracted from the 50 isolates (Fig. 4). CTX-M-15 type ESBL gene was found
143 in 17% of *P.mirabilis*, 25% of *A. baumannii* and 17% of *E. cloacae*,(Fig. 3) *bla* TEM ESBL
144 resistant gene was found in 8.3% of *P. mirabilis*, 35% of *A. baumannii* , none was found in *E.*
145 *cloacae* (Fig. 1) *bla* SHV resistant gene was found in 35% of *A. baumannii* , none was found in *E.*
146 *cloacae* (Fig 3). In this study, antimicrobial susceptibility testing of *A. baumannii*, *E. cloacae*, and
147 *P. mirabilis* isolates originally showed highly significant resistance to different types of
148 antibiotics. This resistance can be due to the presence of specific genes of ESBL such as
149 *bla*TEM, *bla*CTX-M-15 and *bla*SHV. Knowing the types and frequency of these genes helps us
150 to make a good decision for the treatment process of patients effectively.

151 High level of multi-drug resistance including Cefotaxime (CTX), Ceftazidime,(CAZ),
152 Amoxicillin/clavulanic acid (AMC) , Ofloxacin (OFX) and Amikacin (Ak) was observed among
153 the isolates under the study. Various factors, such as the abuse of antibiotics, the spread of clonal
154 resistant microorganisms, can cause the release of highly resistant pathogens. Previous studies
155 showed that the prevalence of *A. baumannii* MDR isolates ranged from 32.7% to 100% [4, 5, 6,
156 7, 8]. Previous researches has reported that the prevalence of ESBL producing *E. cloacae*
157 isolates ranged from 18% to 75% [21, 22] while our studies reports a prevalence of 57% . In the
158 present study 32% of *P. mirabilis* was ESBL producer was consistent with previous studies by
159 Habibu and Orhue [23,24]

160 Among the mechanisms that create resistance to drugs, ESBLs play an important role in
161 resistance to commonly used antibiotics such as penicillin and cephalosporins. ESBL genes, due
162 to the widespread diffusion of pathogens in the community through plasmids and integrons, can
163 further lead to an increase in resistance to drugs including MDR isolates [9].

164 Safari *et al.* reported that *SHV* (58%) and *TEM* (20%) were the highest numbers of ESBL genes
165 in their study (Safari *et al.*,2015). Azhar *et al.* based on a study that conducted in Iraq, reported
166 that *SHV* (25%) was the most frequently detected ESBL gene [28]. Reza *et al.*, reported that
167 *TEM* (52.1) was the most frequently detected ESBL gene [34]. Khalilzadegan and colleagues
168 identified that *CTX-M* and *TEM* have most ESBL genes [26] While in our studies *bla*CTX-M-15
169 (58.3) was the most frequently detected gene.

170 The reason to the observed differences in resistance patterns and the prevalence of *A. baumannii*
171 , *E. cloacae* and *P.mirabilis* in various investigations include the following; abuse and misuse of
172 antibiotics, differences in the type of antibiotics used, long-term hospitalization, type of samples
173 taken, differences in diagnostic methods used to identify genes, geographical conditions, gender
174 and etc [29,30]

175 **Table 2: Frequency of ESBL producing isolates across the three study area**

Bacterial Isolates	Total	%
<i>Acinetobacter baumannii</i>	31	13.5

<i>Acinetobacter haemolyticus</i>	7	3
<i>A. iwoffii</i>	3	1.3
<i>E. coli</i>	10	4.3
<i>Citrobacter youngae</i>	1	0.4
<i>Citrobacter freundii</i>	1	0.4
<i>Citrobacter diversus</i>	1	0.4
<i>Hafnia alvei</i>	17	7.4
<i>Staphylococcus aureus</i>	17	7.4
<i>Enterobacter cloacae</i>	57	24.8
<i>S. maltophilia</i>	12	5.2
<i>Proteus mirabilis</i>	32	13.9
<i>Salmonella subspecies</i>	7	3
<i>P. stuartii</i>	1	0.4
<i>Klebsiella pneumoniae</i>	2	0.7
<i>Enterobacter hormaechei</i>	4	1.7
<i>Enterobacter gresoviae</i>	1	0.4
<i>Serratia marcescens</i>	7	3
<i>Serratia luquefaciens</i>	1	0.4
<i>Morganella morganii</i>	6	2.6
<i>Citrobacter sakazaki</i>	2	0.4

176 **Total** **231** **100**

177

178


179 **Table 3: Detection of *bla*_{ESBL} genes of SHV, TEM and CTX-M-15 in ESBL producing**
 180 ***Proteus mirabilis*, *Acinetobacter baumannii* and *Enterobacter cloacae***

181 No. (%) positive isolates

182


Strain identification	No. of isolates tested	<i>bla</i> _{SHV}	<i>bla</i> _{TEM}	<i>bla</i> _{CTX-M-15}
<i>Proteus mirabilis</i>	12	1(8.3)	1(8.3)	2(16.7)
<i>Acinetobacter baumannii</i>	20	7(35)	7(35)	5(25)
<i>Enterobacter cloacae</i>	18	0	0	3(16.6)
Total	50	8(16)	8(16)	10(20)

183



184
185

186 Figure 1: PCR product of *bla*_{TEM} (Line 1 10kb DNA ladder,5, 7 lower gel) Figure 2: PCR
187 product of *bla*_{SHV} (Line 1:10kb DNA ladder, 4, 5, 6 lower gel) Figure 3:PCR product of *bla*_{CTX-}
188 *M-15* (Line 1:10kb DNA ladder, 2,5, and 6 upper gel, Line 1:10kb DNA ladder, 3,4 lower gel).



189

190 Figure 4:Agarose gel Electrophoresis of plasmids recovered from ESBL producing bacterial
191 isolates. Lane M: 10kb DNA ladder, lanes 1=*P. mirabilis* ,Lanes 5, 6=*A. baumannii* (Upper gel)
192 Lanes 4,5,6 =*E. cloacae*

193 Conclusion

194 In the present study *bla*_{CTX-M-15} had the highest frequency of 58.3% obtained from pregnant
195 women attending antenatal at the three study areas. The biological characteristics of ESBL
196 isolates suggest that the predominant *bla*_{CTX-M-15} is carried by plasmids. Antibiotic use,

197 poverty, hygiene failures has enhance the high increment in ESBL producing Gram negative
198 organism disseminating in African continent [31].

199

200

201

202 **References**

203 1. Akcam, F. Z., Gönen, I., Kaya, O. and Yaylı, G. (2004). The determination of
204 susceptibility of beta-lactam antibiotics and extended spectrum betalactamase production
205 in Enterobacteriaceae which responsible from nosocomial infections. *Med. J. Sdu.* 11: 6-9.

206

207 2. Timko, J .(2004). Changes of antimicrobial resistance and extended spectrum beta-
208 lactamase production in Klebsiella spp. Strains. *J. Infect. Chemother.* 10: 212-215.

209

210 3. Kimura, S., Ishii, Y., Tateda, K. and Yamaguchi, K. (2007). Predictive Analysis of
211 ceftazidime hydrolysis in CTX-M-type β -lactamase family members with a mutational
212 substitution at position 167. *Int. J. Antimicrob. Agents.* 29: 326-331.

213

214 4. Agodi A, Barchitta M, Quattrocchi A, et al.(2015) Antibiotic trends of *Klebsiella*
215 *pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit
216 of Southern Italy, 2008-2013. *Antimicrob Resist Infect Control* 4: 43.

217 5. Mirnejad, R., Vafaei, S.(2013). Antibiotic Resistance patterns and the prevalence of
218 ESBLs among strains of *A. baumannii* isolated from clinical specimens. *J Gen Microbes*
219 *Immunity* 1-8.

220 6. Kheltabadi, R. F., Moniri, R., Shajari, G. R. Nazem Shirazi,. M. H., Musavi, S. G. A.,
221 Ghasemi, A. et al.(2009) Antimicrobial susceptibility patterns and the distribution of
222 resistance genes among acinetobacter species isolated from patients in shahid Beheshti
223 hospital, Kashan. *Feyz J Kashan Univ Med Sci* 12(4)

224 7. Khalilzadegan, S., Sade, M., Godarzi, H., et al(2016) Beta-lactamase encoded genes
225 *bla*TEM and *bla*CTX among *Acinetobacter baumannii* species isolated from medical
226 devices of intensive care units in Tehran hospitals. *Jundishapur J Microbiol* 9(5):
227 e14990.

228 8. Shakibaie, M. R., Adeli, S., Salehi, M. H. (2012). Antibiotic resistance patterns and
229 extended-spectrum β -lactamase production among *Acinetobacter* spp.isolated from an
230 intensive care Unit of a hospital in Kerman, Iran. *Antimicrob Resist Infect Control* 1(1):
231 1.

232 9. Safari, M. M., Nejad, A. S., Bahador, A., Jafari, R., Alikhani, M. Y. (2015). Prevalence
233 of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from
234 patients of intensive care units (ICU). *Saudi J Biol Sci* 22(4): 424-9.

- 235 10. Ribera A, Vila J, Fernández-Cuenca F, et al.(2004) Type 1 integrons in
236 epidemiologically unrelated *Acinetobacter baumannii* isolates collected at Spanish
237 hospitals. *Antimicrob Agents Chemother* 48(1): 364-5
- 238 11. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P (2008). Molecular Characterization
239 and Epidemiology of Extended-Spectrum- β -Lactamase-Producing *Escherichia coli* and
240 *Klebsiella pneumoniae* Isolates Causing Health Care-Associated Infection in Thailand,
241 Where the CTX-M Family Is Endemic. *Antimicrob. Agents Chemother.*, 52: 2818-2824.
- 242 12. Cheng J, Ye Y, Wang YY, Hui L, Xu L, Jia-bin L (2008). Phenotypic and molecular
243 characterization of 5 novel CTX-M enzymes carried by *Klebsiella pneumoniae* and
244 *Escherichia coli*. *Acta Pharmacol. Sin.* 29: 217-225.
- 245
- 246 13. Morris D, O'Hare C, Glennon M, Maher M, Corbett-Feeney G, Cormican M (2003).
247 Extended-Spectrum β -Lactamases in Ireland, Including a Novel Enzyme, TEM-102.
248 *Antimicrob. Agents Chemother.* 47: 2572-2578.
- 249
- 250 14. Paterson David L, Bonomo Robert A. (2005). Extended-spectrum beta-lactamases: a
251 clinical update. *Clin Microbiol Rev*;18(4):657–86
- 252 15. Pitout Johann DD, Nordmann Patrice, Laupland Kevin B, Poirel Laurent (2005)
253 Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)
254 in the community. *J Antimicrob Chemother.*56(1):52–9,
- 255 16. Gazin M, Paasch F, Goostens H, Malhotra-Kumar S.(2012). Current trends in culture
256 based and molecular detection of extended spectrum β -lactamase harbouring and
257 Carbapenem – resistant Enterobacteriaceae. *J Clin Microbiol.* 50(4):1140-1146.
- 258 17. Mohanty, S. Gaiind, R. Ranjan, R. and Deb. M. (2009). Use of cefepime-clavulanate
259 ESBL Etest for detection of extended spectrum beta-lactamase in AmpC co-producing
260 bacteria. *J Infect Dev Ctries.* 4: 24-29
- 261 18. Ben-Ami, R., Rodríguez-Baño, R, Arslan, H, J., et al.(2009). A multinational survey of
262 risk factors for infection with extended-spectrum beta-lactamase-producing
263 enterobacteriaceae in non-hospitalized patients. *Clin Infect Dis*; 49:682.
- 264 19. Jarlier, V., Nicolas, M.-H. Fournier, G. and Philippon. A. (1988). Extended broad-
265 spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in
266 Enterobacteriaceae: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.*
267 10:867–878.
- 268 20. Clinical and Laboratory Standard Institute. (2012). Performance Standard for
269 Antimicrobial susceptibility Testing 22nd informational supplement, M100-S20. Wayne, P
270 A: Clinical and Laboratory Standard Institute
- 271 21. Majid Akbari, Bita Bakhshi and Shahin Najar Peerayeh (2016) Particular Distribution of
272 *Enterobacter cloacae* Strains Isolated from Urinary Tract Infection within Clonal
273 Complexes *Iranian Biomedical Journal* 20(1): 49-55 .
- 274 22. Kobra Salimian Rizi 1, Shahin Najar Peerayeh 1; Bita Bakhshi 1, Mohammad Rahbar 2
275 (2015) Emergence of blaCTX-M-15 Gene and Its Transferability in *Enterobacter spp.*

- 276 Isolated From the Hospitals of Tehran, Iran .*Avicenna J Clin Microb Infec.* August; 2(3):
277 e29691.
- 278 23. Habibu A. U. (2014) Prevalence of *Proteus mirabilis* and *Pseudomonas aeruginosa*
279 among female patients with suspected urinary tract infections attending Muhammad
280 Abdullahi Wase specialist hospital, Kano, Nigeria.
281 *The International Journal Of Engineering And Science (IJES)*; 2319 – 1813 ISSN (p):
282 2319 – 1805
283
- 284 24. Orhue, O. P. (2014). Antibioqram Study of *Proteus* spp. Bacterial Isolates from
285 Uropathogenic Infections in University of Benin Teaching Hospital, Nigeria, *Current*
286 *Research in Bacteriology.* 7(1):12-21.
- 287 25. Safari, M, Mozaffari, N., Bahador, A. S., Jafar, A, Alikhani, M. Y. (2015). Prevalence of
288 ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from
289 patients of intensive care units (ICU). *Saudi J Biol Sci*, 22(4): 424-9
- 290 26. Khalilzadegan S, Sade M, Godarzi H, *et al.* (2016). Beta-lactamase Encoded genes
291 *blaTEM* and *blaCTX* among *Acinetobacter baumannii* species isolated from medical
292 devices of intensive care units in Tehran hospitals. *Jundishapur J Microbiol*; 9(5):
293 e14990
28. Azhar *et al.* (2013). Molecular detection of extended-spectrum betalactamases in
clinical isolates of *A. baumannii*. *J Biol Agric Health* 3(7): 32-9.
- 29.Sedighi, I., Arabestani, M. R., Rahimbakhsh, A., Karimitabar, Z., Alikhani, M. Y.
(2015). Dissemination of extended-spectrum β -lactamases and quinolone resistance genes
among clinical isolates of uropathogenic *Escherichia coli* in children. *Jundishapur J*
Microbiol 8(7): e19184.
30. Darvishi M. Virulence factors profile and antimicrobial resistance of *A. baumannii*
strains isolated from various infections recovered from immunosuppressive patients
2016; 9(3): 1057-62.
31. Woerther ,P. L., Burdet, C., Chachaty., E, Andremont, A. (2013). Trends in human
fecal carriage of Extended-spectrum Beta-lactamase in the community. Towards the
globalization of CTX-M-15 *clin microbial Rev* 26:744-58..
32. Jarlier, V., Nicolas, M. H., Fournier, G. and Philippon, A. (1988). Extended broad-
spectrum beta-lactamases conferring transferable resistance to newer beta-lactam
agents in Enterobacteriaceae: Hospitals Prevalence and susceptibility patterns. *Rev*
Infect Dis. 10(4): 867-78.
33. Glupczynski, Y., Berhin., Bauraing, C., Bogaerts (2007) Evaluation of a new
selective Chromogenic agar medium for detection of Extended spectrum Beta-
lactamase producing Enterobacteriaceae. *J Clin Microbiol.* 42: 501-505.

34. Reza, B., Mohammad, E., *et al* (2019). Prevalence of extended spectrum Beta-lactamase producing *Klebsiella pneumonia*: First systematic review and meta-analysis from Iran. *Journal of Global Antimicrobial Resistance*. 18:12-21.

294

295

296

297

298

299

300

301

302

UNDER PEER REVIEW